JPWO2020144178A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020144178A5
JPWO2020144178A5 JP2021539418A JP2021539418A JPWO2020144178A5 JP WO2020144178 A5 JPWO2020144178 A5 JP WO2020144178A5 JP 2021539418 A JP2021539418 A JP 2021539418A JP 2021539418 A JP2021539418 A JP 2021539418A JP WO2020144178 A5 JPWO2020144178 A5 JP WO2020144178A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable domain
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021539418A
Other languages
Japanese (ja)
Other versions
JP7512290B2 (en
JP2022516351A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/050203 external-priority patent/WO2020144178A1/en
Publication of JP2022516351A publication Critical patent/JP2022516351A/en
Publication of JPWO2020144178A5 publication Critical patent/JPWO2020144178A5/ja
Application granted granted Critical
Publication of JP7512290B2 publication Critical patent/JP7512290B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (4)

がんの治療のための、ヒトＴＩＧＩＴに結合する抗体またはその抗原結合断片を含んでなる医薬組成物であって、
前記がんが肝細胞癌腫、膵臓癌腫、肺癌腫、及びセザリー症候群から選択され、
前記抗体または抗原結合断片が、
配列番号１６を含む重鎖ＣＤＲ１（ＨＣＤＲ１）、配列番号１７を含む重鎖ＣＤＲ２（ＨＣＤＲ２）、配列番号１８を含む重鎖ＣＤＲ３（ＨＣＤＲ３）を含む重鎖可変ドメイン、ならびに
配列番号６１を含む軽鎖ＣＤＲ１（ＬＣＤＲ１）、配列番号６２を含む軽鎖ＣＤＲ２（ＬＣＤＲ２）、及び配列番号６３を含む軽鎖ＣＤＲ３（ＬＣＤＲ３）を含む軽鎖可変ドメイン
を含む、医薬組成物。 A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof that binds to human TIGIT for the treatment of cancer,
said cancer is selected from hepatocellular carcinoma, pancreatic carcinoma, lung carcinoma, and Sézary syndrome;
wherein the antibody or antigen-binding fragment is
a heavy chain variable domain comprising a heavy chain CDR1 (HCDR1) comprising SEQ ID NO: 16, a heavy chain CDR2 (HCDR2) comprising SEQ ID NO: 17, a heavy chain CDR3 (HCDR3) comprising SEQ ID NO: 18, and
A light chain variable domain comprising a light chain CDR1 (LCDR1) comprising SEQ ID NO:61, a light chain CDR2 (LCDR2) comprising SEQ ID NO:62, and a light chain CDR3 (LCDR3) comprising SEQ ID NO:63
A pharmaceutical composition comprising: 前記抗体またはその抗原結合断片が、
配列番号２２１のアミノ酸配列、またはこれに対して少なくとも９０％、９５％、９７％、９８％、もしくは９９％の配列同一性を示すアミノ酸配列を有する、重鎖可変ドメイン
を含み、且つ任意で、
配列番号２２２のアミノ酸配列、またはこれに対して少なくとも９０％、９５％、９７％、９８％、もしくは９９％の配列同一性を示すアミノ酸配列を有する、軽鎖可変ドメイン
を含む、
請求項１に記載の医薬組成物。 wherein the antibody or antigen-binding fragment thereof is
a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 221 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98%, or 99% sequence identity thereto, and optionally,
a light chain variable domain having the amino acid sequence of SEQ ID NO: 222 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98%, or 99% sequence identity thereto;
A pharmaceutical composition according to claim 1 . 前記抗体またはその抗原結合断片が、
配列番号２１９のアミノ酸配列、またはこれに対して少なくとも９０％、９５％、９７％、９８％、もしくは９９％の配列同一性を示すアミノ酸配列を有する、重鎖可変ドメイン
を含み、且つ任意で、
配列番号２２０のアミノ酸配列、またはこれに対して少なくとも９０％、９５％、９７％、９８％、もしくは９９％の配列同一性を示すアミノ酸配列を有する、軽鎖可変ドメイン
を含む、
請求項１に記載の医薬組成物。 wherein the antibody or antigen-binding fragment thereof is
a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 219 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98%, or 99% sequence identity thereto, and optionally,
a light chain variable domain having the amino acid sequence of SEQ ID NO: 220 or an amino acid sequence exhibiting at least 90%, 95%, 97%, 98%, or 99% sequence identity thereto;
A pharmaceutical composition according to claim 1 . 抗ＰＤ１抗体、抗ＰＤ－Ｌ１抗体、抗４１ＢＢ抗体、抗ＯＸ４０抗体、抗ＧＩＴＲ抗体、及び抗ＩＣＯＳ抗体のうちの１つ以上と組み合わせて使用するための、請求項１～３のいずれか一項に記載の医薬組成物。 Any one of claims 1-3, for use in combination with one or more of anti-PD1 antibodies, anti-PD-L1 antibodies, anti-41BB antibodies, anti-OX40 antibodies, anti-GITR antibodies, and anti-ICOS antibodies. The pharmaceutical composition according to .
JP2021539418A 2019-01-07 2020-01-07 Anti-TIGIT antibody Active JP7512290B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789466P 2019-01-07 2019-01-07
US62/789,466 2019-01-07
PCT/EP2020/050203 WO2020144178A1 (en) 2019-01-07 2020-01-07 Anti-tigit antibodies

Publications (3)

Publication Number Publication Date
JP2022516351A JP2022516351A (en) 2022-02-25
JPWO2020144178A5 true JPWO2020144178A5 (en) 2023-01-19
JP7512290B2 JP7512290B2 (en) 2024-07-08

Family

ID=

Similar Documents

Publication Publication Date Title
IL276695A (en) Antibodies, pharmaceutical compositions and uses thereof
JP2017535257A5 (en)
RU2019111722A (en) ANTIBODIES AGAINST SIGLEC-15 AND METHODS OF THEIR APPLICATION
JP2015514110A5 (en)
JP2017048240A5 (en)
HRP20221083T1 (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
JP2013542194A5 (en)
RU2014122990A (en) METHODS OF COMBINED THERAPY WITH APPLICATION OF MOLECULES RELATING TO PSL AND PCRV PSEUDOMONAS
RU2011105062A (en) NEUTRALIZING ANTIBODIES AGAINST INFLUENZA VIRUS A AND THEIR USE
JP2015535828A5 (en)
FI3740504T3 (en) Cd70 combination therapy
JP2012532851A5 (en)
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
JP2017505125A5 (en)
JP2017514461A5 (en)
JP2018535650A5 (en)
JP2017512759A5 (en)
RU2016100892A (en) ANTIBODIES AGAINST TWEAKR AND THEIR APPLICATION
JP2015503909A5 (en)
JP2015504421A5 (en)
JP2016538318A5 (en)
JP2020514310A5 (en)
JP2024024114A5 (en)
IL250289B2 (en) Angiopoietin-like 4 antibodies and methods of use
JP2020522280A5 (en)